Phase II Study of Cabozantinib for Patients with Hard-to-Treat Germ Cell Tumors

Exclusion Criteria

• Previously treated with Cabozantinib.
• Taken any small molecule kinase inhibitor within 2 weeks before starting the study treatment.
• Have not received at least one salvage treatment regimen or have other potential curative treatment options.
• Have untreated or unstable brain metastases unless treated and stable for at least 4 weeks before starting the study treatment.
• Received radiation therapy for bone metastasis within 2 weeks, or any other radiation therapy within 4 weeks before starting the study treatment.
• Planning to father children during the study and up to 120 days after the last dose.
• Treated with any investigational agent or anticancer therapy within 28 days before starting the study treatment.
• Have another active cancer, except for certain skin cancers or other cancers that have not required treatment for at least 1 year.
• Have psychiatric or social conditions that would prevent following the study requirements.
• Have uncontrolled or significant recent illnesses, including:
  • Serious heart conditions like heart failure, unstable chest pain, or serious heart rhythm problems.
  • Uncontrolled high blood pressure.
  • Recent stroke, heart attack, or blood clot within 6 months before starting the study treatment.
  • Certain gastrointestinal disorders with a high risk of complications.
  • Significant bleeding within 12 weeks before starting the study treatment.
  • Lung lesions or disease affecting major airways.
  • Lesions involving major blood vessels.
  • Serious non-healing wounds or fractures.
  • Severe liver impairment.
  • Major surgery within 2 weeks or minor surgery within 10 days before starting the study treatment.
  • Abnormal heart rhythm as shown on an ECG.
  • Taking certain blood thinners that are not allowed in the study.
• Pregnant or breastfeeding women.
• Unable to swallow tablets.
• Known allergy to components of the study treatment.